Hedge fund heavyweight Larry Robbins is one of the industry’s biggest losers this year — but that hasn’t deterred investors from pouring more than $1 billion into his new fund.

Robbins’ Glenview Capital $3.7 billion flagship fund, which focuses on health care stocks, is down 17 percent through November.

That makes it one of the 20 worst-performing hedge funds this year, according to HSBC.

Still, investors ponied up at least $1.5 billion for a new Glenview fund that will only take long positions in stocks, according to a Nov. 20 Glenview regulatory filing. The new fund brings Glenview’s assets to $10 billion.

Most hedge funds also take short positions, but a number of them have also opened long-only funds in recent years as the stock market soared and short bets falter.

Robbins’ health care focus has made him one of the top hedgies in recent years. But this year was an abrupt turn, with Humana and Monsanto, his top two holdings, tanking.

The new fund, available only to current Glenview investors, will not charge performance fees.